Monopar Therapeutics MNPR Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $61.83M+35.0% | $45.82M+531% | $7.27M-11.2% | $8.19M-59.7% | ||
| $60.88M+33.7% | $45.53M+596% | $6.54M-46.3% | $12.18M— | ||
| $140.46M+133% | $60.29M+722% | $7.33M-44.3% | $13.17M-35.8% | ||
| $254.92K— | $0-100% | $12.65K-79.3% | $61.23K— | ||
| $78.57M+446% | $14.4M— | $0-100% | $4.93M— | ||
| $140.72M+133% | $60.29M+721% | $7.35M-44.5% | $13.23M-35.5% | ||
| $2.74M+21.3% | $2.25M+28.3% | $1.76M-43.8% | $3.13M+98.0% | ||
| $90.57K— | $0-100% | $8.41K-85.2% | $56.99K— | ||
| $2.74M-47.9% | $5.25M+199% | $1.76M-43.8% | $3.13M+98.0% | ||
| $154.92K— | $0— | $0-100% | $8.41K— | ||
| $245.49K— | $0-100% | $8.41K-85.2% | $56.99K— | ||
| $2.89M-45.0% | $5.25M+199% | $1.76M-44.0% | $3.14M+98.5% | ||
| $6.69K+9.7% | $6.1K+105% | $2.98K-77.0% | $12.95K+2.8% | ||
| $227.2M+73.7% | $130.79M+98.7% | $65.81M+6.4% | $61.87M+2.7% | ||
| -$89.51M-18.1% | -$75.79M-25.9% | -$60.21M-16.2% | -$51.8M-25.5% | ||
| $131.39K+265% | $35.99K+355% | -$14.13K-258% | $8.94K+383% | ||
| $137.83M+150% | $55.04M+885% | $5.59M-44.6% | $10.09M-46.7% | ||
| $140.72M+133% | $60.29M+721% | $7.35M-44.5% | $13.23M-35.5% | ||
| —— | —— | —— | —— | ||
| $60.88M+33.7% | $45.53M+596% | $6.54M-46.3% | $12.18M— | ||
| $63.75K-19.2% | $78.87K+18.7% | $66.43K+44.5% | $45.98K-78.9% | ||
| $254.92K— | $0-100% | $12.65K-79.3% | $61.23K— | ||
| $78.57M+446% | $14.4M— | $0-100% | $4.93M— | ||
| $254.92K— | $0-100% | $12.65K-79.3% | $61.23K— | ||
| $254.92K— | $0-100% | $12.65K-79.3% | $61.23K— | ||
| $2.74M+21.3% | $2.25M+28.3% | $1.76M-43.8% | $3.13M+98.0% | ||
| $245.49K— | —— | $8.41K-85.2% | $56.99K— | ||
| $227.2M+73.7% | $130.79M+98.7% | $65.81M+6.4% | $61.87M— | ||
| $6.69K+9.7% | $6.1K+105% | $2.98K-77.0% | $12.95K+2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Monopar Therapeutics's total assets?
- Monopar Therapeutics (MNPR) holds $138.0M in total assets, up 150.5% year over year.
- How much debt does Monopar Therapeutics have?
- Monopar Therapeutics carries $230.4K in total debt against $135.4M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Monopar Therapeutics have?
- Monopar Therapeutics holds $52.5M in cash and equivalents.
- Can Monopar Therapeutics cover its short-term obligations?
- Its current ratio is 56.04 — current assets exceed current liabilities.
- Where does Monopar Therapeutics's balance sheet data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.